

**AHCCCS**

**Pharmacy and Therapeutics Committee Meeting Minutes**

May 17, 2016

12:00PM- 4:00 PM

701 E. Jefferson Phoenix, AZ 85034- Gold Room- 3<sup>rd</sup> Floor

**Members Present:**

Dan Lindell  
Stephen Chakmakian  
James Hargrave  
Lydia Neemann  
Robert Marotz  
Berkley Olvera  
Cindy Komar  
Gloria Abril  
Shawn McMahon  
Otto Uhrik  
Kathleen Bryant  
Suzanne Campbell  
Mohamad Ramadan

**AHCCCS Staff:**

Sara Salek  
Suzi Berman  
Robin Davis  
Lauren Prole  
Kathy Bashor

**Magellan Medicaid Admin:**

Doug Brown  
Rick Pope

**Members via teleconference:**

None

**Members Absent:**

Olivia Young  
Joanna Kowalik

**WELCOME AND INTRODUCTIONS: SARA SALEK, M.D., CHIEF MEDICAL OFFICER, AHCCCS**

---

1. Dr. Sara Salek called the meeting to order at 12:00 PM and welcomed committee members, staff, and guest speakers.
- 

**AHCCCS and Behavioral Health Drug Lists**

**SUPPLEMENTAL REBATE CLASS REVIEW**

---

1. Substance Use Disorder
  - a. Clinical review: *Provider Synergies – Doug Pope*
  - b. Pharma Testimony:
    - i. Deborah Profant: Alkermes: Vivitrol
    - ii. William Mullen: Indivior: Suboxone
    - iii. Thomas Begres: Adapt Pharma: Narcan Nasal Spray
    - iv. J Carvel Jackson: Orexo: Zubsolv
  - c. Public Testimony:
    - i. Michael Sucher
    - ii. Lloyd Vacovsky
    - iii. Doray Elkins
    - iv. Kathleen Adams
  
2. Hepatitis C
  - a. Clinical review: *Provider Synergies Rick Pope*
  - b. Pharma Testimony:
    - i. Coleen Fong: Gilead: Harvoni
    - ii. Laura Hill: Abbvie: Viekira Pak
    - iii. John Michael Thomas: Bristol Myers Squibb: Daklinza
    - iv. Ralph Gualtieri: Merck: Zepatier
  - c. Public Testimony:

- i. Mark Wong

3. Hypoglycemics: Incretin Mimetics/Enhancers

- a. Clinical review: *Provider Synergies Dr. Pope*
- b. Pharma Testimony:
  - i. Michele Jones: Novo Nordisk: Victoza
  - ii. Ralph Gualtieri: Merck: Januvia
  - iii. William O'Neill: Boehringer Ingelheim: Jardiance, Glyxambi, Tradjenta
- c. Public Testimony – None

4. Hypoglycemics: Insulin and Related Agents

- a. Clinical review: *Provider Synergies Rick Pope*
- b. Pharma Testimony
  - i. Michele Jones: Novo Nordisk: Tresiba, Levemir, Novolog
  - ii. Nana Numapau: Sanofi: Toujeo
- c. Public Testimony – None

5. COPD

- a. Clinical review: *Provider Synergies Rick Pop* Pharma Testimony
  - i. William O'Neill (Boehringer Ingelheim) Spiriva, Stiolto
- b. Public Testimony – None

6. Executive Session-**Closed to the public**

7. Class Votes

- a. Opioid Dependence Treatment
  - i. Committee members voted unanimously to add the following to the AHCCCS Drug List as preferred products. No members opposed or abstained.
    - 1. Naloxone vial and syringe
    - 2. Naloxone Nasal spray (Narcan)
    - 3. Naltrexone oral (ReVia)
    - 4. Naltrexone ER injectable suspension (Vivitrol)
      - a. Remove PA
    - 5. Buprenorphine/naloxone sublingual flim (Suboxone)
      - a. Remove PA
      - b. No Grandfathering

- ii. Committee members voted unanimously to add the following to the AHCCCS Drug List as preferred products. No members opposed or abstained.
  - 1. Naloxone vial and syringe (solution for injection)
  - 2. Naloxone Nasal Spray (Narcan)
- b. Hepatitis C Agents
  - i. Committee members voted unanimously to add the following to the AHCCCS Drug List as preferred products. No members opposed or abstained.
    - 1. Peg-Intron
    - 2. Pegasys Vial, ProClick, Syringe
    - 3. Ribavirin tablet and capsule
    - 4. Zepatier
    - 5. Technivie
    - 6. Viekira
    - 7. Daklinza
    - 8. Harvoni (currently preferred)
    - 9. Sovaldi (currently preferred)
- c. Hypoglycemics, Incretin Mimetics/Enhancers
  - i. Committee members voted unanimously to add the following to the AHCCCS Drug List as preferred products with grandfathering in place for all except Bydureon pen. No members opposed or abstained.
    - 1. Janumet
    - 2. Janumet XR
    - 3. Januvia
    - 4. Jentadueto
    - 5. Tradjenta
    - 6. Byetta Pens
    - 7. Symlin Pens
    - 8. Victoza
- d. Hypoglycemics, Insulin and Related Agents
  - i. Committee members voted unanimously to add the following to the AHCCCS Drug List as preferred products with no grandfathering. PA status on pen products will be determined after further review. No members opposed or abstained.
    - 1. Humalog vial and pen
    - 2. Humalog mix vial and pen
    - 3. Humulin 70/30 vial
    - 4. Humulin vial

5. Humulin 500 U/M vial and pen
6. Levemir vial and pen
7. Lantus Solostar Pen
8. Lantus vial

e. COPD Agents

- i. Committee members voted unanimously to add the following to the AHCCCS Drug List as preferred products with no grandfathering. No members opposed or abstained.
  1. Ipratropium inhalation solution
  2. Ipratropium/albuterol inhalation solution
  3. Spiriva
  4. Atrovent HFA
  5. Combivent Respimat

**APPROVAL OF FEBRUARY 2016 P&T MEETING MINUTES**

---

1. Motion made by Lydia Nesemann to approve February 2016 meeting minutes
2. Motion seconded by Dr. Marotz
3. 10 committee members voted in favor of approving the minutes
4. 0 committee members opposed
5. 1 committee member abstained

**HCV PRIOR AUTHORIZATION CRITERIA: SUZI BERMAN**

---

The HCV PA Criteria is currently being revised and will be sent out for public comment.

**NEW DRUG REVIEWS: NON-SUPPLEMENTAL REBATE CLASS: RICK POPE/SUZI BERMAN**

---

1. Oncology:
  - a. Recommendation made to form subcommittee to review oral oncology agents
    - i. 8 committee members voted in favor
    - ii. 0 committee members opposed
    - iii. 3 committee members abstained

b. Alecensa

- i. Recommendation is to add Alecensa to the AHCCCS drug list with PA
  - 1. Motion made by Dr. Chakmakian to add Alecensa with PA
  - 2. Motion seconded by Dr. Marotz
  - 3. All committee members voted in favor of the motion
  - 4. No committee members opposed or abstained

c. Cotellic

- i. Recommendation to add Cotellic to the AHCCCS drug list with PA
  - 1. Motion made by Dr. Chakmakian to add Cotellic with PA
  - 2. Motion seconded by Lydia Neemann
  - 3. All committee members voted in favor of the motion
  - 4. No committee members opposed or abstained

d. Ninlaro

- i. Recommended to add Ninlaro to the AHCCCS drug list with PA
  - 1. Motion made by Dr. Chakmakian to add Ninlaro with PA
  - 2. Motion seconded by Dr. Marotz
  - 3. All committee members voted in favor of the motion
  - 4. No committee members opposed or abstained

e. Tagrisso

- i. Recommended to add Tagrisso to the AHCCCS drug list with PA
  - 1. Motion made by Dr. Chakmakian to table in order to research further
  - 2. Motion seconded by Kathleen Bryant
  - 3. All committee members voted in favor of the motion
  - 4. No committee members opposed or abstained

2. Aristada (LAI)

- a. Recommendation is to not add Aristada to the AHCCCS Drug List or the Behavioral Health Drug List and review the long-acting injectable atypical antipsychotics as a supplemental rebate therapeutic class after July 1st.
  - i. Motion made by Kathleen Bryant to table until after July 1<sup>st</sup>
  - ii. Motion seconded by Dr. Chakmakian
  - iii. All committee members voted in favor of the motion
  - iv. No committee members opposed or abstained

3. Belbuca (narcotic, long acting)

- a. Recommendation is to not add Belbuca to the AHCCCS Drug List because there are many other long-acting agents available that are more cost-effective.

- i. Motion made by Dan Lindell to table and review entire class of Opioids for supplemental rebate
  - ii. Motion seconded by Dr. Ramadan
  - iii. All committee members voted in favor of the motion
  - iv. No committee members opposed or abstained
4. Dyanavel XR (stimulants)
  - a. Recommendation is to not add Dyanavel XR to the AHCCCS Drug List or the Behavioral Health Drug List because there are other more cost effective stimulants available on these drug lists.
    - i. Motion Made by Dr. Chakmakian to remain off of the AHCCCS Drug List
    - ii. Motion seconded by Lydia Neemann
    - iii. All committee members voted in favor of the motion
    - iv. No committee members opposed or abstained
5. Genvoya (HIV/AIDS)
  - a. Recommendation is to add Genvoya to the AHCCCS Drug List with prior authorization.
    - i. Motion made by Dan Lindell to add to the AHCCCS Drug list with no prior authorization
    - ii. Motion seconded by Dr. Marotz
    - iii. 5 committee members voted in favor of the motion
    - iv. 0 committee members Opposed
    - v. 6 committee members Abstained
6. Invega Trinza (LAI)
  - a. Recommendation is not to add Invega Trinza to the AHCCCS drug list and review as a supplemental rebate therapeutic class after July 1st.
    - i. Motion made by Kathleen Bryant to table and review entire class after July 1<sup>st</sup>.
    - ii. Motion seconded by Lydia Neemann
    - iii. All committee members voted in favor of the motion
    - iv. No committee members opposed or abstained
7. Keveysis (CAI)
  - a. Recommendation to add Keveysis to the AHCCCS drug list with prior authorization
    - i. Motion made by Lydia Neemann to leave off of the AHCCCS drug list as a non preferred agent and make available via PA only.
    - ii. Motion seconded by Dr. Chakmakian
    - iii. 10 committee members voted in favor of the motion
    - iv. No committee members opposed
    - v. 1 committee member abstained

8. Quillichew ER (stimulants)
  - a. Recommended to not add Quillichew ER to the AHCCCS or Behavioral Health drug list because many other Methylphenidate products are more cost effective.
    - i. Motion made by Dr. Chakmakian to leave off of the AHCCCS and Behavioral Health Drug lists.
    - ii. Motion seconded by Kathleen Bryant
    - iii. All committee members voted in favor of the motion
    - iv. No committee members opposed or abstained
9. Uptravi (PAH)
  - a. Recommended to not add Uptravi to the AHCCCS drug list as there are several other options currently available on the drug list.
    - i. Motion made by Lydia Neemann not to add Uptravi to the AHCCCS drug list
    - ii. Motion seconded by Kathleen Bryant
    - iii. All committee members voted in favor of the motion
    - iv. No committee members abstained
10. Rexulti (antipsychotic/MDD)
  - a. Recommendation is not to add Rexulti to the AHCCCS preferred drug list or the Behavioral Health drug list
    - i. Motion made by Kathleen Bryant to table until after July 1<sup>st</sup>
    - ii. Motion seconded by Dan Lindell
    - iii. All committee members voted in favor of the motion
    - iv. No committee members opposed or abstained

## **BIOLOGIC UPDATE: SUZI BERMAN**

---

1. Glatopa (Biosimilar for Copaxone)
  - a. Per the AHCCCS Medical Policy Manual: Policy 310V:
    - i. AHCCCS Contractors shall not transition to a biosimilar drug until AHCCCS has determined that the biosimilar drug is overall more cost-effective to the state than the continued use of the brand name drug.
  - b. AHCCCS and its contractors shall continue to cover only the brand name Copaxone because it is more cost effective than Glatopa.

**P&T OPERATIONAL POLICY: SARA SALEK**

---

Discussion Tabled until August 2017 P&T meeting

**AGENDA ITEMS FOR AUGUST 16, 2016 P&T: ALL**

---

Please email Suzi Berman any requests for agenda items for the August 2016 meeting.

**ADJOURNMENT**

---

The meeting adjourned at 5:20 PM  
Minutes recorded by Robin Davis

*Suzi Berman, RPh*

Suzi Berman, RPh  
Director of Pharmacy Services  
AHCCCS

Date: August 16, 2016